John McHutchison
Director/Board Member bei ASSEMBLY BIOSCIENCES, INC.
Vermögen: 282 239 $ am 31.05.2023
Profil
John G.
McHutchison is the founder of Actio Biosciences, Inc. (founded in 2021).
He is currently the President & Chief Executive Officer at Velia, Inc. (since 2023), a Director at Assembly Biosciences, Inc. (since 2019), a Director at Evox Therapeutics Ltd.
(since 2021), a Director at Tune Therapeutics, Inc. (since 2023), and a Member of The Royal Australasian College of Physicians.
Previously, he served as a Director at Oxford BioTherapeutics Ltd.
(2017-2023), Associate Director at Duke Clinical Research Institute, Medical Director-Liver Transplantation at Scripps Clinic & Research Foundation, and Independent Director at Metacrine, Inc. (2020-2023).
He was also the Chief Scientific Officer and Head of R&D at Gilead Sciences, Inc. (2018-2019).
Additionally, he held positions as an Assistant Professor at the University of Southern California and a Professor at Duke University Medical Center.
Dr. McHutchison completed his undergraduate and doctorate degrees at the University of Melbourne.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
01.04.2024 | 21 221 ( 0,39% ) | 282 239 $ | 31.03.2024 | |
METACRINE INC
-.--% | 03.02.2023 | 0 ( -.--% ) | - $ | 31.05.2023 |
Aktive Positionen von John McHutchison
Unternehmen | Position | Beginn |
---|---|---|
ASSEMBLY BIOSCIENCES, INC. | Director/Board Member | 06.08.2019 |
The Royal Australasian College of Physicians | Corporate Officer/Principal | - |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Director/Board Member | 18.01.2021 |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Director/Board Member | 17.01.2023 |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Chief Executive Officer | 19.07.2023 |
Ehemalige bekannte Positionen von John McHutchison
Unternehmen | Position | Ende |
---|---|---|
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Director/Board Member | 24.04.2023 |
METACRINE, INC. | Director/Board Member | 23.03.2023 |
GILEAD SCIENCES, INC. | Chief Tech/Sci/R&D Officer | 02.08.2019 |
Actio Biosciences, Inc.
Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Founder | - |
░░░░░░░ ░░░░░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Ausbildung von John McHutchison
University of Melbourne | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
GILEAD SCIENCES, INC. | Health Technology |
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
METACRINE, INC. | Health Technology |
Private Unternehmen | 8 |
---|---|
Oxford BioTherapeutics Ltd.
Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Duke Clinical Research Institute
Duke Clinical Research Institute Pharmaceuticals: OtherHealth Technology Duke Clinical Research Institute manufactures medical and botanical products. It offers specialized patient databases and clinical and operational expertise. The firm accelerates the development of therapies, diagnostics, and medical devices to humans. The company was founded in 1969 and is headquartered in Durham, NC. | Health Technology |
Scripps Clinic & Research Foundation | |
The Royal Australasian College of Physicians | |
Evox Therapeutics Ltd.
Evox Therapeutics Ltd. BiotechnologyHealth Technology Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom. | Health Technology |
Tune Therapeutics, Inc.
Tune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tune Therapeutics, Inc. is a genetic medicine company based in Durham, NC. Tune Therapeutics is pioneering a new therapeutic modality with its versatile and powerful tempo epigenomic control platform. The platform has the potential to fine-tune any gene network and unlock the full power and potential of regenerative medicine. The company is driving through an inflection point in the history of genetic medicine by addressing thousands of common and complex diseases for which no curative treatment is available. Tune Therapeutics pioneers next-generation genetic therapies by exploring epigenomic control for discovering novel targets that are inaccessible to other approaches. The company was founded in 2020 by Fyodor Urnov, Akira Matsuno, Charles A. Gersbach. The CEO is Matt Kane. | Health Technology |
Velia, Inc.
Velia, Inc. Packaged SoftwareTechnology Services Velia, Inc. is a company based in San Francisco, CA that is focused on harnessing the therapeutic potential of a novel class of human peptides. These peptides regulate biological functions that are vital to human health. The company was founded by Alan Saghatelian, Jonathan Weissman, Eric Olson, and Richard Scheller. John G. McHutchison has been the CEO of the company since 2023. | Technology Services |
Actio Biosciences, Inc.
Actio Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors. | Health Technology |